NeuroPace raises 2026 revenue guidance to $99M-$101M range, signaling strong market demand for its neuromodulation devices. The medical technology company projects underlying RNS growth between 21% and 23% percent, demonstrating accelerating adoption in epilepsy treatment. During its Q1 earnings call, management highlighted positive FDA developments and improved operational margins as key drivers of the outlook. The guidance increase reflects growing patient demand and expanded clinical adoption of the company's implantable seizure management system. Investors are watching closely as NeuroPace continues to capture market share in the specialized neuromodulation sector, where competition remains limited and clinical evidence supports long-term patient outcomes.
Post from MarketNews_en
Log in to interact with content.